- Design
- Systematic review and meta-analysis of 19 mainly uncontrolled studies
- Population
- 445 patients with relapsing or refractory lupus nephritis
- Primary outcome
- Complete, partial and overall renal response at 6, 12 and 24 months
- Effect
- Complete response 41% (95% CI 28 to 54) and overall response 70% (51 to 86) at 12 months
A meta-analysis in Clinical and Translational Science (1 October 2026) pooled 19 studies of 445 patients given rituximab, as rescue or add-on therapy, for relapsing or refractory lupus nephritis.
Complete renal response was 33% at 6 months, 41% at 12 months and 42% at 24 months. Overall response, complete or partial, was about two-thirds at each point. Proteinuria fell by 2.7 g a day and creatinine by about 12 µmol/L.
The included studies were mostly uncontrolled and small, so these are response rates in treated patients, not proof that rituximab caused them. Still, they give realistic expectations for a widely used off-label option in patients who have failed standard therapy, in India as elsewhere.
- Consider rituximab for relapsing or refractory lupus nephritis after standard induction has failed.
- Set realistic expectations: about four in ten reached complete response by a year.
- Check hepatitis B status and immunoglobulins before giving rituximab.
- Reassess with a repeat biopsy if response stalls, to separate activity from chronic damage.
Why it matters
It puts numbers on an off-label option that is widely used but rarely quantified in this setting.
Don't overread it
The data come from uncontrolled studies; they show response rates, not that rituximab outperforms alternatives.
The statistics, in plain English
A pooled complete response of 41% with a confidence interval of 28% to 54% means the true rate could plausibly be anywhere from about a quarter to over half. Without control groups, some responses may reflect other treatment changes or the natural course.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free